Your browser is no longer supported. Please, upgrade your browser.
NEW! Auto Refresh is now available in Screener. Let us know what you think. ×
PRGO Perrigo Company Public Limited Company monthly Stock Chart
Perrigo Company Public Limited Company
IndexS&P 500 P/E156.91 EPS (ttm)0.96 Insider Own0.10% Shs Outstand146.40M Perf Week-3.14%
Market Cap22.05B Forward P/E16.08 EPS next Y9.37 Insider Trans-7.10% Shs Float145.20M Perf Month-3.52%
Income144.30M PEG11.32 EPS next Q1.93 Inst Own78.30% Short Float1.60% Perf Quarter-19.89%
Sales5.00B P/S4.41 EPS this Y-48.30% Inst Trans-1.18% Short Ratio1.14 Perf Half Y-20.72%
Book/sh73.36 P/B2.05 EPS next Y21.03% ROA1.30% Target Price194.58 Perf Year-3.44%
Cash/sh3.57 P/C42.16 EPS next 5Y13.86% ROE2.40% 52W Range140.28 - 215.26 Perf YTD-9.62%
Dividend0.50 P/FCF23.81 EPS past 5Y-17.60% ROI3.90% 52W High-30.02% Beta0.32
Dividend %0.33% Quick Ratio1.20 Sales past 5Y15.20% Gross Margin38.80% 52W Low7.38% ATR5.54
Employees13500 Current Ratio1.70 Sales Q/Q41.30% Oper. Margin18.50% RSI (14)44.43 Volatility2.59% 3.30%
OptionableYes Debt/Eq0.50 EPS Q/Q6.90% Profit Margin4.80% Rel Volume0.46 Prev Close150.00
ShortableYes LT Debt/Eq0.49 EarningsOct 22 BMO Payout28.40% Avg Volume2.03M Price150.63
Recom2.00 SMA20-4.03% SMA50-5.91% SMA200-14.64% Volume940,000 Change0.42%
Nov-24-15Reiterated B. Riley & Co. Buy $229 → $237
Nov-18-15Resumed JP Morgan Neutral
Nov-16-15Upgrade UBS Neutral → Buy $200
Oct-23-15Reiterated B. Riley & Co. Neutral $218 → $229
Jun-03-15Reiterated B. Riley & Co. Neutral $195 → $216
Apr-27-15Downgrade B. Riley & Co. Buy → Neutral
Apr-22-15Reiterated B. Riley & Co. Buy $189 → $195
Apr-10-15Downgrade Argus Buy → Hold
Feb-06-15Reiterated RBC Capital Mkts Outperform $177 → $175
Nov-12-14Reiterated Argus Buy $160 → $175
Nov-07-14Reiterated RBC Capital Mkts Outperform $169 → $177
Sep-22-14Reiterated RBC Capital Mkts Outperform $160 → $169
May-15-14Reiterated Argus Buy $175 → $160
May-08-14Reiterated B. Riley & Co. Neutral $170 → $157
May-08-14Downgrade RBC Capital Mkts Top Pick → Outperform $187 → $160
Mar-03-14Reiterated UBS Buy $176 → $190
Mar-03-14Reiterated Stifel Buy $165 → $175
Feb-25-14Reiterated CRT Capital Buy $165 → $175
Feb-07-14Downgrade B. Riley & Co. Buy → Neutral
Jan-16-14Reiterated Argus Buy $160 → $175
Nov-26-15 02:37PM  Hedge Funds Are Buying Health Care REIT, Inc. (HCN) at Insider Monkey
Nov-25-15 09:53AM  EXCLUSIVE: FBB's Mike Bailey On Pfizer-Allergan Deal, Taxes, Rate Hike And Biotech Picks
12:00AM  Mylan, Bruised by Failed Perrigo Bid, Set for Face-Off on Assets at Bloomberg
Nov-24-15 04:08PM  Billionaire James Dinan Loaded Up On These Stocks For Q4 at Insider Monkey
03:30PM  AstraZeneca to Divest Entocort U.S. Rights to Perrigo
Nov-23-15 08:25PM  PRESS DIGEST- Financial Times - Nov 24
04:53PM  Perrigo (PRGO) Stock Declined on AstraZeneca Drug Rights Deal at TheStreet
12:15PM  AstraZeneca (AZN) Stock Rises After Selling Crohn's Disease Drug to Perrigo at TheStreet
12:00PM  China Drives Another Nail in the Coffins of GNC and Vitamin Shoppe
09:41AM  AstraZeneca sells Crohn's disease drug for $380M at
07:56AM  Perrigo Furthers Rx "Extended Topicals" Strategy With The Acquisition Of Leading Gastrointestinal Product Entocort® PR Newswire
07:35AM  AstraZeneca sells US rights for gastro drug to Perrigo for $380m at Financial Times
07:26AM  10 Stocks Billionaire John Paulson Is Buying in 2015 at TheStreet
02:25AM  AstraZeneca sells U.S. drug rights to Perrigo for $380 mln
Nov-19-15 01:29PM  Perrigo CEO: Go Back to What Has Made Us Strong
Nov-18-15 08:06AM  Why Did Mylans Share Price Rise after Its Offer Was Rejected?
Nov-17-15 08:39AM  Hedge Fund Round-Up For Q3 13F Season
08:22AM  Perrigo Considered Mylans Offer to Be Dilutive to EPS
08:22AM  Why Perrigos Shareholders Rejected Mylans Tender Offer
Nov-16-15 04:25PM  Mylan's Acquisition Offer Fails to Woo Perrigo Shareholders
02:25PM  Mylan Led SPY with a Rise of 12.9%
01:05PM  What Perrigo and Teva Can Learn From Mylans Share Repurchase at 24/7 Wall St.
11:53AM  Mylan to buy back $1 bln in stock
Nov-15-15 09:21PM  Your entire closet, '25' and a 'censored' film festival are on the minds of our women to watch at
07:20AM  Generic Drugmakers Block Suitors, but Is That Good or Bad News? at Motley Fool
Nov-14-15 09:20AM  7 BioHealth Movers That Cannot Be Ignored at 24/7 Wall St.
12:41AM  [$$] Mylan-Perrigo Deal: What Is the Price of Failure? at The Wall Street Journal
12:39AM  [$$] Mylan Loses Hostile Bid for Perrigo at The Wall Street Journal
Nov-13-15 11:51PM  [$$] Mylan Loses Hostile Bid for Perrigo at The Wall Street Journal -6.16%
06:55PM  Mylan Bid For Perrigo Fails On Shareholder Vote at Investor's Business Daily
05:28PM  PERRIGO CO PLC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Sta
04:48PM  Hedge funds take a beating on Perrigos stock at MarketWatch
04:37PM  Perrigo shareholders reject Mylan's hostile $26B takeover bid at USA TODAY
03:52PM  Perrigo Company plc -- Moody's affirms Perrigo's Baa3 rating; stable outlook at Moody's
03:44PM  Perrigo Shareholders Give Thumbs Down to $34 Billion Mylan Offer at TheStreet
02:17PM  Why Mylan Just Lost The Largest Hostile Takeover Battle Ever at Fortune
01:09PM  Did Mylan Win By Losing Perrigo? at
12:50PM  Yum Brands boosted by China sales growth at Financial Times
12:34PM  Mylan N.V.'s Hostile Takeover Attempt of Perrigo Fails -- Investors Cheer at Motley Fool
12:33PM  TIMELINE-Mylan fails in $26 bln takeover bid for Perrigo Reuters
12:26PM  4 Stocks, 4 trades: FIT, LOCO, FOSL & PRGO
12:13PM  Why These Stocks Are Tanking Today at Insider Monkey
11:49AM  Perrigo Merger, Act II at Bloomberg
10:34AM  Stocks Falter At Start Of Trade; Fossil, El Pollo, GameStop Slide at Investor's Business Daily
10:33AM  Perrigo to go it alone; shareholders reject $26B Mylan bid
10:02AM  Perrigo's shareholders reject Mylan takeover bid at CNBC
10:00AM  Perrigo shareholders reject Mylan
09:56AM  Perrigo Shareholders Thwart Mylan's Hostile Takeover Bid
09:49AM  Dealpolitik: Perrigo Victory Challenges Conventional Wisdom at The Wall Street Journal
09:42AM  Perrigo (PRGO) Stock Plunging on Failed Mylan Deal at TheStreet
09:37AM  Mylan fails in $27bn pursuit of Perrigo at Financial Times
09:34AM  Stocks Lower as Retail Sales Muddy Interest Rates Outlook at TheStreet
09:21AM  Perrigo Shareholders Convincingly Reject Mylan's Tender Offer, Expressing Confidence in Perrigo's Long-Term Strategy PR Newswire
09:19AM  Mylan (MYL) Stock Soars, Loses $26 Billion Hostile Bid for Perrigo at TheStreet
09:18AM  Mylan fails in $26 bln bid to buy fellow drugmaker Perrigo
09:00AM  Mylan loses hostile bid for Perrigo at MarketWatch
08:51AM  Perrigo plunges after Mylan bid flops
08:50AM  Mylan says 40 percent of Perrigo shares tendered, misses goal
08:43AM  Mylan's Hostile Bid for Perrigo Fails
08:42AM  Shareholders of drugmaker Perrigo shut the door on Mylan and its $26B, hostile takeover bid
08:39AM  Mylan Announces Results of Offer to Acquire Perrigo and Lapse of Offer PR Newswire
07:25AM  Mylan Gains, Perrigo Falls as Takeover Offer Is Seen Failing at Bloomberg
07:25AM  Mylan Gains, Perrigo Falls as Hostile Takeover Bid Seen Failing
07:13AM  Mylans Hostile Bid for Perrigo Looks Like Its Going to Fail at Fortune
12:36AM  [$$] Mylan Set to Lose in $26 Billion Hostile Takeover Battle for Perrigo at The Wall Street Journal
Nov-12-15 11:56PM  [$$] Mylan Set to Lose in $26 Billion Hostile Takeover Battle for Perrigo at The Wall Street Journal
11:37PM  Mylan's tender offer for Perrigo unlikely to succeed -sources
11:01PM  Mylan's tender offer for Perrigo unlikely to succeed -source
12:18PM  Mylan, Perrigo Face Off As Takeover Vote Nears at Investor's Business Daily
12:17PM  Mylan-targeted Perrigo held merger talks with Endo -sources
11:33AM  Mylan's Perrigo Bid Keeps Investors Guessing as Deadline Nears at Bloomberg
05:53AM  Mylan / Perrigo: innocents abroad at Financial Times
12:10AM  [$$] Mylan Hostile Takeover Bid for Perrigo Is Rare Nail Biter at The Wall Street Journal
Nov-11-15 08:39PM  [$$] Mylan Hostile Takeover Bid for Perrigo Is Rare Nail Biter at The Wall Street Journal
08:15PM  [$$] Mylan Hostile Takeover Is a Rare Nail Biter at The Wall Street Journal
11:38AM  Mylan's Last-Minute Leverage at Bloomberg
11:10AM  Perrigo: Mylan 'resorting to desperate tactics' in takeover at
Nov-10-15 01:39PM  PERRIGO CO PLC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
09:54AM  Perrigo Reaffirms Views on Mylan's Inadequate Offer; Maintains Strong Recommendation Shareholders Not Tender PR Newswire
08:24AM  Perrigo Announces FDA Approval Of The AB Rated Generic Version Of KlorCon® Extended-Release Tablets PR Newswire
07:00AM  Mylan Highly Confident in Successful Completion of Tender Offer for Perrigo on Friday PR Newswire
12:35AM  [$$] Dealpolitik: A Roadmap for Exiting Mylan Governance Prison at The Wall Street Journal
12:34AM  [$$] Mylans Hostile Offer Puts Perrigo CFO to the Test at The Wall Street Journal
Nov-09-15 09:56PM  [$$] Mylan's Hostile Offer Puts Perrigo CFO to the Test at The Wall Street Journal
08:07PM  [$$] Hostile Bid Puts CFO Of Perrigo to the Test at The Wall Street Journal
06:33PM  Dealpolitik: A Roadmap for Exiting Mylan Governance Prison
04:40PM  Dealpolitik: A Roadmap for Exiting Mylan 'Governance Prison' at The Wall Street Journal
10:53AM  These Stocks Are in Spotlight on M&A-Related News at Insider Monkey
10:44AM  Perrigo at mercy of shareholders
06:57AM  Perrigo Issues Shareholder Letter PR Newswire
06:55AM  Perrigo Responds to Misleading Statements PR Newswire
Nov-06-15 01:04PM  PERRIGO CO PLC Financials
Nov-04-15 11:17AM  Mylan not relying on acquisitions if Perrigo bid fails -chairman Reuters
08:49AM  Perrigo Company plc Announces Quarterly Dividend PR Newswire
04:11AM  Mylan Lists in Tel Aviv in Latest Salvo in Perrigo Battle at Bloomberg
Nov-03-15 04:56PM  Mylan agrees to divest seven generics in Perrigo fight
04:48PM  FTC clears Mylan's $27B proposed takeover of Perrigo
04:38PM  [$$] FTC Clears Mylan's Proposed Takeover of Perrigo at The Wall Street Journal
04:10PM  FTC approves Mylan's hostile bid for Perrigo with conditions Reuters
03:18PM  Mylan Receives U.S. FTC Clearance for Proposed Acquisition of Perrigo and Confirms Governance Changes for the Combined Mylan-Perrigo Company PR Newswire
Perrigo Company plc, through its subsidiaries, develops, manufactures, and markets over-the-counter (OTC) consumer goods and pharmaceutical products worldwide. The company operates through Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals (Rx Pharmaceuticals), Specialty Sciences, and Other segments. The CHC segment offers OTC products, including analgesics, cough/cold/allergy/sinus, gastrointestinal, infant nutritional, smoking cessation, animal health, feminine hygiene, diabetes and dermatological care, diagnostic, and other healthcare products, as well as vitamins, minerals, and dietary supplements; and contract manufacturing services. It serves retail drug, supermarket, mass merchandise chains, and wholesalers through sales force and industry brokers. The BCH segment provides branded OTC products in the natural health; vitamins, minerals, and supplements; cough, cold, and allergy; personal care and derma-therapeutics; lifestyle; and anti-parasite areas. This segment serves pharmacies, drug, and grocery stores through pharmacy sales force, as well as a network of pharmacists. The Rx Pharmaceuticals segment offers generic and specialty pharmaceutical prescription drugs in various dosage forms, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, powders, controlled substances, injectables, hormones, women's health products, oral solid dosage forms, and oral liquid formulations; and ORx products. It serves wholesalers; retail drug, supermarket, and mass merchandise chains; hospitals; and pharmacies. The Specialty Sciences segment provides Tysabri to treat multiple sclerosis. The Other segment offers active pharmaceutical ingredients that are used by generic and branded pharmaceutical companies. The company was founded in 1887 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gottfried RanDirectorNov 19Option Exercise100.842,726274,89015,454Nov 23 04:17 PM
Gottfried RanDirectorNov 19Sale154.342,726420,72212,728Nov 23 04:17 PM
MORRIS HERMAN JRDirectorNov 18Sale155.6455085,602850Nov 20 07:35 PM
KUNKLE GARY K JRDirectorNov 13Option Exercise146.901,929283,37026,133Nov 17 04:57 PM
JANDERNOA MICHAEL JDirectorNov 13Option Exercise146.901,929283,3702,797Nov 17 04:57 PM
BRLAS LAURIEDirectorNov 13Option Exercise146.901,929283,37010,903Nov 17 04:58 PM
Hoffing Ellen RandiDirectorNov 13Option Exercise146.901,929283,3709,530Nov 17 04:56 PM
FOUSE JACQUALYN ADirectorNov 13Option Exercise146.901,929283,3704,362Nov 17 04:56 PM
COHEN GARY MDirectorNov 13Option Exercise146.901,929283,37013,797Nov 17 04:56 PM
MORRIS HERMAN JRDirectorNov 13Option Exercise146.901,929283,3705,057Nov 17 04:57 PM
O'Connor DonalDirectorNov 13Option Exercise146.901,929283,3702,173Nov 17 04:57 PM
GIBBONS DAVID TDirectorNov 04Option Exercise162.291,929313,05715,104Nov 05 04:16 PM
Gottfried RanDirectorNov 04Option Exercise162.291,929313,05713,654Nov 06 05:22 PM
HENDRICKSON JOHN TEVP Global Operations & SupplyAug 25Sale181.371,737315,0400Aug 27 03:32 PM
KINGMA TODD WExecutive VP, General CounselAug 25Sale181.371,715311,05010,320Aug 27 03:32 PM
HENDRICKSON JOHN TEVP Global Operations & SupplyAug 24Option Exercise114.604,468512,0314,131Aug 25 06:21 PM
HENDRICKSON JOHN TEVP Global Operations & SupplyAug 24Sale177.684,468793,8701,737Aug 25 06:21 PM
Jamison Scott FExecutive Vice President PBMAug 21Option Exercise186.89552103,1635,379Aug 25 06:21 PM
Stewart Michael RobertSr. VP Global Human ResourcesAug 21Option Exercise186.89552103,1631,398Aug 25 06:21 PM
Shah JatinSr VP & Chief Scientific OfficAug 21Option Exercise186.89552103,1634,619Aug 25 06:22 PM
Needham JeffreyEVP, GM Consumer HealthcareAug 21Option Exercise186.89967180,7237,646Aug 25 06:20 PM
Kochan SharonEVP, GM InternationalAug 21Option Exercise186.89967180,7237,731Aug 25 06:20 PM
PAPA JOSEPH CPresident and CEOAug 21Option Exercise186.897,3651,376,445123,234Aug 25 06:21 PM
HENDRICKSON JOHN TEVP Global Operations & SupplyAug 21Option Exercise186.891,022191,0022,223Aug 25 06:21 PM
Farrington ThomasSenior VP and CIOAug 21Option Exercise186.89552103,1631,719Aug 25 06:19 PM
Boothe DouglasEVP & GM Perrigo PharmaAug 21Option Exercise186.8939573,822951Aug 25 06:19 PM
KINGMA TODD WExecutive VP, General CounselAug 21Option Exercise186.891,409263,32812,686Aug 25 06:19 PM
Yu LouisExecutive VP Global QualityAug 21Option Exercise186.89552103,1636,327Aug 25 06:20 PM
Brown Judy LExecutive VP & CFOAug 21Option Exercise186.892,578481,80213,621Aug 25 06:20 PM
KINGMA TODD WExecutive VP, General CounselApr 29Option Exercise58.821,70099,99411,064May 01 04:19 PM
KINGMA TODD WExecutive VP, General CounselApr 29Sale190.271,700323,4599,364May 01 04:19 PM
HENDRICKSON JOHN TEVP Global Operations & SupplyApr 14Option Exercise107.058,800941,9974,148Apr 16 04:14 PM
HENDRICKSON JOHN TEVP Global Operations & SupplyApr 14Sale200.278,8001,762,3760Apr 16 04:14 PM
KINGMA TODD WExecutive VP, General CounselApr 13Option Exercise35.851,30046,60510,664Apr 15 02:57 PM
KINGMA TODD WExecutive VP, General CounselApr 13Sale198.441,300257,9729,364Apr 15 02:57 PM
Shah JatinSr VP & Chief Scientific OfficMar 13Sale165.502,000331,0003,291Mar 17 10:50 AM
Yu LouisExecutive VP Global QualityMar 12Sale166.2714023,2784,746Mar 16 04:35 PM
Farrington ThomasSenior VP and CIOFeb 20Sale151.1851778,161321Feb 24 04:26 PM
Farrington ThomasSenior VP and CIOFeb 06Option Exercise0.0079801,119Feb 09 04:37 PM